BACKGROUND: Human T-lymphotropic virus (HTLV)-I and HTLV-II cause chronic human retroviral infections, but few studies have examined the impact of either virus on survival among otherwise healthy individuals. The authors analyzed all-cause and cancer mortality in a prospective cohort of 155 HTLV-I, 387 HTLV-II, and 799 seronegative subjects. METHODS: Vital status was ascertained using death certificates, the US Social Security Death Index or family report, and causes of death were grouped into 9 categories. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models. RESULTS: After a median follow-up of 15.9 years, there were 105 deaths: 22 HTLV-I, 41 HTLV-II, and 42 HTLV-seronegative. Cancer was the predominant cause of death, resulting in 8 HTLV-I, 17 HTLV-II, and 15 HTLV-seronegative deaths. After adjustment for confounding, HTLV-I status was not significantly associated with increased all-cause mortality, though there was a positive trend (HR: 1.6, 95% CI: 0.8 to 3.1). HTLV-II status was strongly associated with increased all-cause (HR: 2.4, 95% CI: 1.4 to 4.4) and cancer mortality (HR: 3.8, 95% CI: 1.6 to 9.2). CONCLUSIONS: The observed associations of HTLV-II with all-cause and cancer mortality could reflect biological effects of HTLV-II infection, residual confounding by socioeconomic status or other factors, or differential access to health care and cancer screening.
BACKGROUND:Human T-lymphotropic virus (HTLV)-I and HTLV-II cause chronic humanretroviral infections, but few studies have examined the impact of either virus on survival among otherwise healthy individuals. The authors analyzed all-cause and cancer mortality in a prospective cohort of 155 HTLV-I, 387 HTLV-II, and 799 seronegative subjects. METHODS: Vital status was ascertained using death certificates, the US Social Security Death Index or family report, and causes of death were grouped into 9 categories. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models. RESULTS: After a median follow-up of 15.9 years, there were 105 deaths: 22 HTLV-I, 41 HTLV-II, and 42 HTLV-seronegative. Cancer was the predominant cause of death, resulting in 8 HTLV-I, 17 HTLV-II, and 15 HTLV-seronegative deaths. After adjustment for confounding, HTLV-I status was not significantly associated with increased all-cause mortality, though there was a positive trend (HR: 1.6, 95% CI: 0.8 to 3.1). HTLV-II status was strongly associated with increased all-cause (HR: 2.4, 95% CI: 1.4 to 4.4) and cancer mortality (HR: 3.8, 95% CI: 1.6 to 9.2). CONCLUSIONS: The observed associations of HTLV-II with all-cause and cancer mortality could reflect biological effects of HTLV-II infection, residual confounding by socioeconomic status or other factors, or differential access to health care and cancer screening.
Authors: C Boschi-Pinto; S Stuver; A Okayama; D Trichopoulos; E J Orav; H Tsubouchi; N Mueller Journal: J Infect Dis Date: 2000-01 Impact factor: 5.226
Authors: J R Orland; J Engstrom; J Fridey; R A Sacher; J W Smith; C Nass; G Garratty; B Newman; D Smith; B Wang; K Loughlin; E L Murphy Journal: Neurology Date: 2003-12-09 Impact factor: 9.910
Authors: A Visconti; L Visconti; R Bellocco; N Binkin; G Colucci; L Vernocchi; M Amendola; D Ciaci Journal: J Acquir Immune Defic Syndr (1988) Date: 1993-11
Authors: Edward L Murphy; Baoguang Wang; Ronald A Sacher; Joy Fridey; James W Smith; Catharie C Nass; Bruce Newman; Helen E Ownby; George Garratty; Shelia T Hutching; George B Schreiber Journal: Emerg Infect Dis Date: 2004-01 Impact factor: 6.883
Authors: Anna Bárbara F Carneiro-Proietti; Ester C Sabino; Silvana Leão; Nanci A Salles; Paula Loureiro; Moussa Sarr; David Wright; Michael Busch; Fernando A Proietti; Edward L Murphy Journal: AIDS Res Hum Retroviruses Date: 2012-05-03 Impact factor: 2.205
Authors: Anat Melamed; Aviva D Witkover; Daniel J Laydon; Rachael Brown; Kristin Ladell; Kelly Miners; Aileen G Rowan; Niall Gormley; David A Price; Graham P Taylor; Edward L Murphy; Charles R M Bangham Journal: PLoS Pathog Date: 2014-03-13 Impact factor: 6.823
Authors: James M Fox; Nora Mutalima; Elizabeth Molyneux; Lucy M Carpenter; Graham P Taylor; Martin Bland; Robert Newton; Fabiola Martin Journal: Trop Med Int Health Date: 2016-02-03 Impact factor: 2.622
Authors: Benjamin Usadi; Roberta Bruhn; Jue Lin; Tzong-Hae Lee; Elizabeth Blackburn; Edward L Murphy Journal: Viruses Date: 2016-08-11 Impact factor: 5.048